• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Alexander Varshavsky     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatFellowsOfTheAmericanAssociationForTheAdvancementOfScience, within Data Space : dbpedia.org associated with source document(s)

Type: Thingpersonyago:WikicatAmericanBiochemistsyago:WikicatAmericanMedicalResearchersyago:WikicatAmericanPeopleyago:WikicatAmericanPeopleOfRussianDescentyago:WikicatBiochemistsyago:WikicatLivingPeopleyago:Associate109816771yago:Biochemist109854915yago:CausalAgent100007347yago:Chemist109913824yago:Colleague109935990yago:LivingThing100004258yago:Object100002684yago:Organism100004475yago:Peer109626238yago:Person100007846yago:PhysicalEntity100001930yago:ResearchWorker110523076yago:YagoLegalActoryago:YagoLegalActorGeoyago:Scientist110560637yago:Whole100003553yago:WikicatFellowsOfTheAmericanAssociationForTheAdvancementOfScience New Facet based on Instances of this Class

Alexander Jacob Varshavsky (Russian: Александр Яковлевич Варшавский; born 8 November 1946) is a Russian-American biochemist, noted for his discovery of the N-end rule of ubiquitination. A native of Moscow, he is currently researching at Caltech. The approach termed deletion-specific targeting (DST), employs HDs (homozygous DNA deletions) as the targets of cancer therapy. "In contrast to other attributes of cancer cells, their HDs are immutable markers. If the DST strategy can be implemented in a clinical setting, it may prove to be both curative and free of side effects."